PHARMACOLOGY UPDATE

Etelcalcetide Injection (Parsabiv)

March 15, 2017

Etelcalcetide is indicated for secondary hyperparathyroidism in adult patients presenting with chronic kidney disease and who are on hemodialysis.

Issue Date: March 15, 2017

Table of Contents

Financial Disclosure: Internal Medicine Alert’s Physician Editor Stephen Brunton, MD, is a retained consultant for Abbott Diabetes, Actavis, AstraZeneca, Becton Dickinson, Boehringer Ingelheim, Cempra, Janssen, Lilly, Merck, Novo Nordisk, Sanofi, and Teva; he serves on the speakers bureau of AstraZeneca, Boehringer Ingelheim, Janssen, Lilly, Novo Nordisk, and Teva. Contributing Editor Louis Kuritzky, MD, is a retained consultant for and on the speakers bureau of, Allergan, Daiichi Sankyo, Lilly, and Lundbeck. Peer Reviewer Gerald Roberts, MD; Executive Editor Leslie Coplin; and Editor Jonathan Springston report no financial relationships relevant to this field of study.

Subscription Publication Books & Study Guides Group & Site Licenses State CME/CE Requirements